Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer
Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 18(2022), 4 vom: 21. Feb., Seite 491-503 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stone, Rebecca L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epithelial ovarian cancer |
|---|
| Anmerkungen: |
Date Completed 18.03.2022 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2021-0567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334124891 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334124891 | ||
| 003 | DE-627 | ||
| 005 | 20231225223042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2021-0567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334124891 | ||
| 035 | |a (NLM)34875854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stone, Rebecca L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2022 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a epithelial ovarian cancer | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a patient preferences | |
| 650 | 4 | |a physician preferences | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Cambron-Mellott, M Janelle |e verfasserin |4 aut | |
| 700 | 1 | |a Beusterien, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Maculaitis, Martine C |e verfasserin |4 aut | |
| 700 | 1 | |a Ritz, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Mulvihill, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Monberg, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Szamreta, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Suvina |e verfasserin |4 aut | |
| 700 | 1 | |a McLaurin, Kimmie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 4 vom: 21. Feb., Seite 491-503 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:4 |g day:21 |g month:02 |g pages:491-503 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2021-0567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 4 |b 21 |c 02 |h 491-503 | ||